Does Your CGM Still Work Right at Altitude?
The chemistry behind a continuous glucose monitor depends on oxygen, which raises a real question for anyone using one somewhere the air is thinner.
This piece covers the mechanism behind CGM accuracy concerns at altitude and the design of the first randomized trial built to test it under controlled hypoxia. It does not report the trial's specific accuracy results, which are not part of the evidence available for this piece.
The two most common consumer and clinical CGM systems, FreeStyle Libre and Dexcom G6, rely on glucose-oxidase chemistry that depends on oxygen availability, and that dependency is well established for how these sensors work. What has been genuinely untested, until researchers built a trial specifically to check it, is whether real hypoxia, the kind encountered at altitude, on a flight, or in certain medical conditions, actually changes how accurate those sensors are once oxygen availability drops.
A sensor built on a gas most people never think about
A continuous glucose monitor gets treated like any other wearable sensor, something that just reads a number off the body without much thought to how. What that framing skips over is that the two most widely used CGM systems work through an enzymatic reaction that needs oxygen to function, the same glucose-oxidase chemistry used in a lot of glucose testing technology generally.
That detail matters more in some settings than others. Altitude, air travel, and certain medical conditions all reduce how much oxygen is actually available in the body. And until recently, nobody had run a controlled test of what that does to a CGM's accuracy.
1 study
- The two glucose-oxidase-based CGM systems most commonly used, FreeStyle Libre and Dexcom G6, are described as well established for accuracy under normal oxygen conditions, but the study notes that little evidence existed on their performance during hypoxia, the kind encountered at altitude, during air travel, or in certain medical conditions. A randomized controlled trial was designed specifically to close that gap, exposing 30 participants, 15 healthy volunteers and 15 with diabetes, to standardized normobaric hypoxia while wearing both sensor types simultaneously, with venous plasma glucose as the reference measurement and induced glycemic swings from a standardized meal and moderate cycling exercise.
What the trial was built to answer
The design itself tells you what the open question actually was: not whether these sensors work in everyday, sea-level conditions, which the study describes as well established, but whether the same accuracy holds once oxygen availability drops in a controlled, standardized way. Using normobaric hypoxia rather than a real ascent let researchers isolate the oxygen variable specifically, rather than mixing in cold, exertion, or altitude sickness as confounds.
Running both healthy volunteers and participants with diabetes through the same testing approach, and comparing both sensor brands against a lab-grade venous blood reference rather than each other, was built to produce a genuine answer to whether hypoxia degrades CGM accuracy and by how much. The mean absolute relative difference between sensor and reference glucose served as the primary measure.
What this piece can't tell you
The evidence available here describes the trial's design and rationale in detail, but not its reported outcome. Whether accuracy held up under hypoxia, degraded, or changed differently between the two sensor brands is the actual result of the trial, and that result isn't part of what this piece can responsibly report from the source material at hand.
That's a real gap, not a minor one, for anyone specifically wondering whether their own CGM readings without diabetes can be trusted at elevation. The mechanism for concern is confirmed. The trial built to test it exists and was well designed for the question. What it actually found isn't something this piece can state without overstepping what the evidence here supports.
This piece is built from a summary of the FOX study's design, population, and methodology. It does not include the trial's reported accuracy results, mean absolute relative difference figures, or error-grid findings, so no claim about whether CGM accuracy actually changes under hypoxia can be made from the material available here.
Common questions
Why would altitude affect a CGM's accuracy?
The two most common CGM systems, FreeStyle Libre and Dexcom G6, use glucose-oxidase chemistry that depends on oxygen availability, which is well established as how these sensors work, and altitude reduces how much oxygen is available in the body.
Has CGM accuracy actually been tested under low-oxygen conditions?
A randomized controlled trial was specifically designed to test this, exposing 30 participants, both healthy volunteers and people with diabetes, to standardized hypoxia while wearing both sensor types and comparing readings against a lab-grade blood glucose reference.
Does this mean CGMs are inaccurate at altitude?
This piece cannot answer that. It describes the trial's design and the mechanism behind the concern, but the trial's actual reported accuracy results are not part of the evidence available here.
Does this apply to air travel as well as mountain altitude?
The trial used standardized normobaric hypoxia to simulate reduced oxygen availability broadly, which the source material frames as relevant to altitude exposure, air travel, and certain medical conditions collectively, rather than testing each setting separately.